×
S&P 500   3,845.08 (+0.36%)
DOW   31,037.68 (+0.23%)
QQQ   288.74 (+0.62%)
AAPL   142.80 (+0.88%)
MSFT   266.14 (+1.25%)
META   169.77 (+0.94%)
GOOGL   2,291.11 (+1.14%)
AMZN   114.26 (+0.67%)
TSLA   694.30 (-0.70%)
NVDA   151.30 (+1.11%)
NIO   20.81 (-6.18%)
BABA   119.25 (-0.73%)
AMD   75.37 (+0.23%)
MU   57.37 (+1.13%)
CGC   2.65 (-2.21%)
T   21.09 (-0.38%)
GE   61.56 (-0.76%)
F   11.07 (-1.16%)
DIS   96.11 (-1.10%)
AMC   12.58 (-1.56%)
PFE   52.75 (+2.15%)
PYPL   73.24 (-1.56%)
NFLX   184.06 (-0.98%)
S&P 500   3,845.08 (+0.36%)
DOW   31,037.68 (+0.23%)
QQQ   288.74 (+0.62%)
AAPL   142.80 (+0.88%)
MSFT   266.14 (+1.25%)
META   169.77 (+0.94%)
GOOGL   2,291.11 (+1.14%)
AMZN   114.26 (+0.67%)
TSLA   694.30 (-0.70%)
NVDA   151.30 (+1.11%)
NIO   20.81 (-6.18%)
BABA   119.25 (-0.73%)
AMD   75.37 (+0.23%)
MU   57.37 (+1.13%)
CGC   2.65 (-2.21%)
T   21.09 (-0.38%)
GE   61.56 (-0.76%)
F   11.07 (-1.16%)
DIS   96.11 (-1.10%)
AMC   12.58 (-1.56%)
PFE   52.75 (+2.15%)
PYPL   73.24 (-1.56%)
NFLX   184.06 (-0.98%)
S&P 500   3,845.08 (+0.36%)
DOW   31,037.68 (+0.23%)
QQQ   288.74 (+0.62%)
AAPL   142.80 (+0.88%)
MSFT   266.14 (+1.25%)
META   169.77 (+0.94%)
GOOGL   2,291.11 (+1.14%)
AMZN   114.26 (+0.67%)
TSLA   694.30 (-0.70%)
NVDA   151.30 (+1.11%)
NIO   20.81 (-6.18%)
BABA   119.25 (-0.73%)
AMD   75.37 (+0.23%)
MU   57.37 (+1.13%)
CGC   2.65 (-2.21%)
T   21.09 (-0.38%)
GE   61.56 (-0.76%)
F   11.07 (-1.16%)
DIS   96.11 (-1.10%)
AMC   12.58 (-1.56%)
PFE   52.75 (+2.15%)
PYPL   73.24 (-1.56%)
NFLX   184.06 (-0.98%)
S&P 500   3,845.08 (+0.36%)
DOW   31,037.68 (+0.23%)
QQQ   288.74 (+0.62%)
AAPL   142.80 (+0.88%)
MSFT   266.14 (+1.25%)
META   169.77 (+0.94%)
GOOGL   2,291.11 (+1.14%)
AMZN   114.26 (+0.67%)
TSLA   694.30 (-0.70%)
NVDA   151.30 (+1.11%)
NIO   20.81 (-6.18%)
BABA   119.25 (-0.73%)
AMD   75.37 (+0.23%)
MU   57.37 (+1.13%)
CGC   2.65 (-2.21%)
T   21.09 (-0.38%)
GE   61.56 (-0.76%)
F   11.07 (-1.16%)
DIS   96.11 (-1.10%)
AMC   12.58 (-1.56%)
PFE   52.75 (+2.15%)
PYPL   73.24 (-1.56%)
NFLX   184.06 (-0.98%)
NASDAQ:RZLT

Rezolute Stock Forecast, Price & News

$3.15
-0.18 (-5.41%)
(As of 07/6/2022 03:59 PM ET)
Add
Compare
Today's Range
$3.15
$3.20
50-Day Range
$2.60
$3.85
52-Week Range
$2.26
$13.08
Volume
514 shs
Average Volume
136,227 shs
Market Capitalization
$105.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.25

Rezolute MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
473.9% Upside
$18.25 Price Target
Short Interest
Healthy
0.13% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$279,995 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.44) to ($2.13) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.94 out of 5 stars

Medical Sector

421st out of 1,426 stocks

Pharmaceutical Preparations Industry

195th out of 682 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive RZLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rezolute and its competitors with MarketBeat's FREE daily newsletter.

Rezolute logo

About Rezolute (NASDAQ:RZLT) Stock

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

RZLT Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RZLT
Fax
N/A
Employees
26
Year Founded
N/A

Company Calendar

Last Earnings
5/12/2022
Today
7/06/2022
Next Earnings (Estimated)
9/21/2022
Fiscal Year End
6/30/2023

Price Target and Rating

Average Stock Price Forecast
$18.25
High Stock Price Forecast
$25.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+479.4%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
4 Analysts

Profitability

Net Income
$-20,900,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.12 per share

Miscellaneous

Free Float
28,478,000
Market Cap
$105.78 million
Optionable
Not Optionable
Beta
3.00














Rezolute Frequently Asked Questions

Should I buy or sell Rezolute stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rezolute in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Rezolute stock.
View analyst ratings for Rezolute
or view top-rated stocks.

What is Rezolute's stock price forecast for 2022?

4 equities research analysts have issued 12 month target prices for Rezolute's shares. Their RZLT stock forecasts range from $9.00 to $25.00. On average, they anticipate Rezolute's stock price to reach $18.25 in the next twelve months. This suggests a possible upside of 473.9% from the stock's current price.
View analysts' price targets for Rezolute
or view top-rated stocks among Wall Street analysts.

How has Rezolute's stock price performed in 2022?

Rezolute's stock was trading at $4.78 at the beginning of 2022. Since then, RZLT shares have decreased by 33.5% and is now trading at $3.18.
View the best growth stocks for 2022 here
.

When is Rezolute's next earnings date?

Rezolute is scheduled to release its next quarterly earnings announcement on Wednesday, September 21st 2022.
View our earnings forecast for Rezolute
.

How were Rezolute's earnings last quarter?

Rezolute, Inc. (NASDAQ:RZLT) issued its earnings results on Thursday, May, 12th. The company reported ($0.65) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.86) by $0.21.
View Rezolute's earnings history
.

Who are Rezolute's key executives?

Rezolute's management team includes the following people:
  • Mr. Nevan Charles Elam J.D., Founder, CEO & Director (Age 55, Pay $1.01M)
  • Dr. Brian Kenneth Roberts M.D., Sr. VP & Head of Clinical Devel. (Age 46, Pay $744.74k)
  • Mr. Chris Milks, VP & Head of Fin.
  • Mr. Michael R. Deperro, Sr. VP & Head of Technical Operations
  • Dr. Davelyn Eaves Hood M.B.A., M.D., Director and Head of Scientific & Patient Affairs
  • Mr. Michael Covarrubias, VP & Head of CMC
  • Dr. Raj Agrawal M.D., VP & Head of Ophthalmological Clinical Devel.
  • Ms. Robyn Sweinhart, VP & Head of Quality
  • Ms. Erin O'Boyle, VP & Head of Clinical Operations

What other stocks do shareholders of Rezolute own?

What is Rezolute's stock symbol?

Rezolute trades on the NASDAQ under the ticker symbol "RZLT."

How do I buy shares of Rezolute?

Shares of RZLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rezolute's stock price today?

One share of RZLT stock can currently be purchased for approximately $3.18.

How much money does Rezolute make?

Rezolute (NASDAQ:RZLT) has a market capitalization of $106.78 million. The company earns $-20,900,000.00 in net income (profit) each year or ($3.15) on an earnings per share basis.

How many employees does Rezolute have?

Rezolute employs 26 workers across the globe.

How can I contact Rezolute?

Rezolute's mailing address is 201 REDWOOD SHORES PARKWAY SUITE 315, REDWOOD CITY CA, 94065. The official website for Rezolute is www.rezolutebio.com. The company can be reached via phone at (650) 206-4507 or via email at investor-relations@rezolutebio.com.

This page (NASDAQ:RZLT) was last updated on 7/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.